Literature DB >> 33478278

BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.

Esther Sathya Bama Benjamin1, Niveditha Ravindra1, Bharathi Murugan Rajamani1, Senthamizhselvi Anandan1, Bagavathi Kausalya2, Vidya Veldore2, Vikram Mathews1, Shaji Ramachandran Velayudhan, Poonkuzhali Balasubramanian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33478278      PMCID： PMC7611165          DOI： 10.1080/10428194.2021.1872074

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  13 in total

1.  Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.

Authors:  Katerina Machova Polakova; Vojtech Kulvait; Adela Benesova; Jana Linhartova; Hana Klamova; Monika Jaruskova; Caterina de Benedittis; Torsten Haferlach; Michele Baccarani; Giovanni Martinelli; Tomas Stopka; Thomas Ernst; Andreas Hochhaus; Alexander Kohlmann; Simona Soverini
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-04       Impact factor: 4.553

2.  Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.

Authors:  Simona Soverini; Caterina De Benedittis; K Machova Polakova; Adela Brouckova; David Horner; Michele Iacono; Fausto Castagnetti; Gabriele Gugliotta; Francesca Palandri; Cristina Papayannidis; Ilaria Iacobucci; Claudia Venturi; Maria Teresa Bochicchio; Hana Klamova; Federica Cattina; Domenico Russo; Paola Bresciani; Gianni Binotto; Barbara Giannini; Alexander Kohlmann; Torsten Haferlach; Andreas Roller; Gianantonio Rosti; Michele Cavo; Michele Baccarani; Giovanni Martinelli
Journal:  Blood       Date:  2013-06-21       Impact factor: 22.113

3.  Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Authors:  Constance Baer; Wolfgang Kern; Sarah Koch; Niroshan Nadarajah; Sonja Schindela; Manja Meggendorfer; Claudia Haferlach; Torsten Haferlach
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

4.  Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.

Authors:  Aytug Kizilors; Elena Crisà; Nicholas Lea; Roberto Passera; Syed Mian; Jamal Anwar; Steve Best; Franck E Nicolini; Robin Ireland; Maadh Aldouri; Christopher Pocock; Tim Corbett; Richard Gale; Emily Bart-Smith; Simon Weston-Smith; Clare Wykes; Austin Kulasekararaj; Sophie Jackson; Patrick Harrington; Donal McLornan; Kavita Raj; Antonio Pagliuca; Ghulam J Mufti; Hugues de Lavallade
Journal:  Lancet Haematol       Date:  2019-05       Impact factor: 18.959

5.  Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Authors:  Su Chu; Helen Xu; Neil P Shah; David S Snyder; Stephen J Forman; Charles L Sawyers; Ravi Bhatia
Journal:  Blood       Date:  2004-09-02       Impact factor: 22.113

6.  Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.

Authors:  Yucel Erbilgin; Ahmet Emre Eskazan; Ozden Hatirnaz Ng; Ayse Salihoglu; Tugrul Elverdi; Sinem Firtina; Orcun Tasar; Sevcan Mercan; Sinem Sisko; Khusan Khodzhaev; Seniz Ongoren; Muhlis Cem Ar; Zafer Baslar; Teoman Soysal; Muge Sayitoglu; Ugur Ozbek
Journal:  Leuk Lymphoma       Date:  2018-07-02

7.  Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

Authors:  Wendy T Parker; Musei Ho; Hamish S Scott; Timothy P Hughes; Susan Branford
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

8.  Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.

Authors:  Simona Soverini; Caterina De Benedittis; Katerina Machova Polakova; Jana Linhartova; Fausto Castagnetti; Gabriele Gugliotta; Cristina Papayannidis; Manuela Mancini; Hana Klamova; Marzia Salvucci; Monica Crugnola; Alessandra Iurlo; Francesco Albano; Domenico Russo; Gianantonio Rosti; Michele Cavo; Michele Baccarani; Giovanni Martinelli
Journal:  Oncotarget       Date:  2016-04-19

Review 9.  Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.

Authors:  Simona Soverini; Elisabetta Abruzzese; Monica Bocchia; Massimiliano Bonifacio; Sara Galimberti; Antonella Gozzini; Alessandra Iurlo; Luigiana Luciano; Patrizia Pregno; Gianantonio Rosti; Giuseppe Saglio; Fabio Stagno; Mario Tiribelli; Paolo Vigneri; Giovanni Barosi; Massimo Breccia
Journal:  J Hematol Oncol       Date:  2019-12-05       Impact factor: 17.388

10.  Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.

Authors:  Bharathi M Rajamani; Esther Sathya Bama Benjamin; Aby Abraham; Sukanya Ganesan; Kavitha M Lakshmi; Senthamizhselvi Anandan; Sreeja Karathedath; Savitha Varatharajan; Ezhilpavai Mohanan; Nancy Beryl Janet; Vivi M Srivastava; Shaji Ramachandran Velayudhan; Uday P Kulkarni; Anup J Devasia; N A Fouzia; Anu Korula; Biju George; Alok Srivastava; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.